Skip to main content

Table 2 Impact of ATG4B expression levels on overall survival by the different demographic and clinicopathologic factors with colorectal cancer

From: ATG4B and pS383/392-ATG4B serve as potential biomarkers and therapeutic targets of colorectal cancer

Variable

 

No. (%)

CHR (95% CI)

p value*

AHR (95% CI)

p value †

Sex

      

 Female

Low

25 (53.5)

1.00

 

1.00

 

High

22 (46.5)

2.14 (0.90–5.10)

0.087

3.69 (1.43–9.53)

0.007 a

 Male

Low

38 (53.2)

1.00

 

1.00

 

High

33 (46.8)

3.92 (1.79–8.58)

0.001

6.59 (2.81–15.46)

< 0.001 a

Age, yrs

      

 ≦ 60

Low

22 (48.9)

1.00

 

1.00

 

High

23 (51.1)

3.45 (1.24–9.60)

0.018

4.94 (1.72–14.24)

0.003 a

 >60

Low

41 (56.2)

1.00

 

1.00

 

High

32 (43.8)

2.94 (1.44–5.98)

0.003

6.74 (2.83–16.01)

< 0.001 a

Cell differentiation

      

 Well

Low

3 (68.0)

1.00

 

1.00

 

High

1 (32.0)

434.45 (0.00-8.954E + 12)

0.616

434.45 (0.00-8.954E + 12)

0.616b

 Moderate, poor

Low

60 (44.1)

1.00

 

1.00

 

High

54 (55.9)

3.07 (1.69–5.58)

< 0.001

5.90 (3.07–11.32)

< 0.001 b

AJCC pathological stage

      

 I, II

Low

23 (41.1)

1.00

 

1.00

 

High

33 (58.9)

2.60 (0.85–7.97)

0.096

3.00 (0.85–10.54)

0.087c

 III, IV

Low

40 (64.5)

1.00

 

1.00

 

High

22 (35.5)

6.18 (3.00-12.72)

< 0.001

6.14 (2.97–12.70)

< 0.001 c

T classification

      

 T1, T2

Low

12 (57.1)

1.00

 

1.00

 

High

9 (42.9)

3.22 (0.59–17.64)

0.178

5.50 (0.61–49.32)

0.128d

 T3, T4

Low

51 (52.6)

1.00

 

1.00

 

High

46 (47.4)

3.01 (1.62–5.59)

< 0.001

4.73 (2.40–9.31)

< 0.001 d

N classification

      

 N0

Low

27 (42.2)

1.00

 

1.00

 

High

37 (57.8)

2.60 (1.03–6.56)

0.043

2.65 (0.97–7.25)

0.059e

 N1, N2

Low

36 (66.7)

1.00

 

1.00

 

High

18 (33.3)

6.10 (2.77–13.43)

< 0.001

6.02 (2.71–13.35)

< 0.001 e

Postoperative RT

      

 No

Low

56 (50.9)

1.00

 

1.00

 

High

54 (49.1)

2.83 (1.56–5.14)

0.001

4.88 (2.59–9.21)

< 0.001 a

 Yes

Low

7 (87.5)

1.00

 

1.00

 

High

1 (12.5)

22097.29 (0.00-1.528E + 052)

0.859

22097.29 (0.00-1.528e + 052)

0.859a

  1. Abbreviations: SCC, squamous cell carcinoma; CHR, crude hazard ratio; CI, confidence interval; AHR, adjusted hazard ratio; AJCC, American Joint Committee on Cancer; RT, radiotherapy.
  2. *p values were estimated by Cox’s regression.
  3. † p values were estimated by multivariate Cox’s regression.
  4. a Adjusted for cell differentiation (moderate + poor vs. well) and AJCC pathological stage (stage III + IV vs. stage I + II).
  5. b Adjusted for AJCC pathological stage (stage III + IV vs. stage I + II).
  6. c Adjusted for cell differentiation (moderate + poor vs. well).
  7. d Adjusted for cell differentiation (moderate + poor vs. well) and N classification (N1, N2 vs. N0).
  8. e Adjusted for cell differentiation (moderate + poor vs. well) and T classification (T3, T4 vs. T1 + T2).